March 24, 2023

Vascudyne’s First-in-Human Study Results Gain International Recognition in Leading Renal Publication

Vascudyne’s groundbreaking first-in-human clinical trial of the acellular tissue-engineered vessel (ATEV) has gained significant attention in the medical community, with Renal Interventions featuring the company’s published results from the Journal of Vascular Access. The international coverage highlights the study’s demonstration that the Vascudyne ATEV is “safe and feasible” for haemodialysis access, with five patients achieving 80% primary patency and 100% secondary patency at six months. Critically, there was no infection in any of the patients and no specific IgG antibody response was seen in any patients, demonstrating excellent biocompatibility of this completely biological regenerative conduit.

The recognition underscores the significant clinical potential of Vascudyne’s technology to address critical limitations in current hemodialysis access options. As corresponding author Dr. Zeeshan Syedain explained to Renal Interventions, “Completely biological regenerative tissue conduits are designed to mimic the structure and function of natural blood vessels, potentially improving longevity and performance of haemodialysis graft. This study demonstrate initial safety, mechanical durability and lack of immune response with TRUE AVC and as a potential off-the-shelf blood vessel conduit for clinical use.” The study’s authors emphasized that the Vascudyne ATEV represents “an off-the-shelf, completely biological acellular vascular conduit, able to repopulate with the recipient’s own cells and become a living vessel in vivo”, with larger cohort studies planned to further validate this innovative approach to vascular access.